Elon Musk said on October 30, 2026, in posts on X, that Blindsight, Neuralink's second product, is ready from an engineering standpoint and is only waiting on regulatory approval. This claim is classified here as a STATEMENT: it is the founder's word, not an approval announcement or a clinical result.
According to Musk, Blindsight “will enable even those who are completely blind or have never seen to see.” His exact words were: “It is ready from an engineering standpoint. Just waiting on regulatory approval.”
How Blindsight is supposed to work
The device is a visual prosthesis: instead of trying to repair the eyes, it aims to bypass damaged eyes or optic nerves. A camera captures images of the surroundings, and the implant sends that visual information directly to the brain's visual cortex, the region that processes sight.
What has not been proven yet
The statement must be separated from what has been demonstrated. Blindsight received the U.S. Food and Drug Administration's Breakthrough Device Designation in September 2024. That designation speeds up dialogue and review, but it is not an approval and does not show that the device restores vision in people.
So far, Neuralink has not announced a first Blindsight implant in a human or a date for one, and the visual implant's clinical trials are still described by the company as future studies in preparation. In other words, the engineering readiness Musk claims is not the same as proven clinical effectiveness.
On the same day, Musk also discussed the company's first product, Telepathy, designed to enable communication through thought, and predicted that within a few years its bandwidth would exceed the fastest human speech or typing. That prediction is also a statement, not a measured result — and Telepathy remains an investigational device without FDA commercial approval.
The practical next step runs through clinical trials designed to show safety and real benefit, followed by regulatory review of that evidence. Until those results appear, Blindsight should be treated as a project in development, not as an available treatment.
Image credit: illustration of the Blindsight implant published by The Gadget Flow in coverage of the FDA designation.
Sources: Digital Trends; ShiftDelete; TechTimes UK
Transparency: this article was produced with the assistance of artificial intelligence, cross-checked against public posts on X and internet sources. We recommend consulting the original sources for more details.
Muse
